VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
January 03, 2024 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative...
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023 07:45 ET
|
VYNE Therapeutics Inc.
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for...
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
November 07, 2023 08:00 ET
|
VYNE Therapeutics Inc.
Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment...
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
November 01, 2023 16:15 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative...
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202
October 30, 2023 07:20 ET
|
VYNE Therapeutics Inc.
Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritisFollowing completion...
VYNE Therapeutics Announces Private Placement of $88 Million
October 30, 2023 07:05 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative...
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo
October 30, 2023 07:00 ET
|
VYNE Therapeutics Inc.
Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was...
VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary,...
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023 08:00 ET
|
VYNE Therapeutics Inc.
Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 IND-enabling studies for VYN202, a potential...
VYNE Therapeutics to Attend BIO International Convention
May 18, 2023 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary,...